Inceptive

Inceptive is a private, pre-revenue biotech company pioneering an end-to-end AI platform for drug discovery. The company's core approach involves training foundation models on heterogeneous biological data and iteratively validating designs through its integrated wet lab, aiming to generate breakthrough drug candidates with properties superior to existing options. Founded by AI and biochemistry pioneers, Inceptive operates with a unique 'antedisciplinary' culture and has offices in Palo Alto, Berlin, and Zurich, positioning itself as a next-generation AI-native drug developer.

End-to-end AI foundation models trained on heterogeneous, multi-scale biological data (sequence, structure, function), integrated with a high-throughput wet lab for iterative design, validation, and model improvement. The platform is engineered to extrapolate beyond training data to design novel therapeutic molecules with superior properties.

Inceptive competes in the crowded AI-driven drug discovery space against companies like Recursion, Exscientia, Insilico Medicine, and Absci, as well as internal initiatives at large pharmaceutical firms. Its key claimed differentiators are its end-to-end foundation model approach, the tight integration of a proprietary wet lab for rapid validation, and a focus on designing molecules that extrapolate beyond known data.